Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xbrane Biopharma AB ( (SE:XBRANE) ) has issued an update.
Xbrane Biopharma AB has announced a teleconference for investors, analysts, and media to discuss its interim report for January to September 2025, scheduled for October 24, 2025. The presentation, led by CEO Martin Åmark and CFO Jane Benyamin, will provide insights into the company’s performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK23.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a company that develops biological drugs using a patented platform technology, which significantly reduces production costs compared to competing systems. The company has a portfolio of biosimilar candidates targeting an estimated EUR 23 billion in annual peak sales of the respective reference products. Xbrane’s lead candidate, Ximluci®, has received market authorization approval in Europe and was launched in 2023. The company is headquartered in Solna, near Stockholm, and is listed on Nasdaq Stockholm under the ticker XBRANE.
YTD Price Performance: 15.93%
Average Trading Volume: 119,085
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK480.1M
Learn more about XBRANE stock on TipRanks’ Stock Analysis page.